Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
2 studies found for:    23075178 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
Condition: Crohn's Disease
Interventions: Drug: Placebo (IP);   Drug: Ustekinumab 1mg/kg (IP);   Drug: Ustekinumab 3 mg/kg (IP);   Drug: Ustekinumab 6 mg/kg (IP);   Drug: Placebo IV - Responder - Placebo SC (MP);   Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP);   Drug: Ustekinumab IV - Responder - Placebo SC (MP);   Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP);   Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP);   Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
2 Recruiting Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Conditions: CVID;   Enteropathy;   Chronic Diarrhea;   Maldigestion;   Malabsorption
Intervention: Biological: Ustekinumab

Study has passed its completion date and status has not been verified in more than two years.